Heron Therapeutics (NASDAQ:HRTX) Releases Earnings Results, Meets Estimates

Heron Therapeutics (NASDAQ:HRTX) issued its earnings results on Monday. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03), FiscalAI reports. Heron Therapeutics had a negative return on equity of 237.56% and a negative net margin of 14.55%. The business had revenue of $35.25 million during the quarter, compared to analysts’ expectations of $37.50 million.

Heron Therapeutics Price Performance

Heron Therapeutics stock opened at $0.37 on Wednesday. The business’s fifty day moving average is $0.33 and its two-hundred day moving average is $0.66. The company has a debt-to-equity ratio of 24.35, a quick ratio of 1.51 and a current ratio of 2.49. The firm has a market cap of $71.02 million, a P/E ratio of -3.12 and a beta of 1.65. Heron Therapeutics has a 52 week low of $0.26 and a 52 week high of $1.57.

Key Heron Therapeutics News

Here are the key news stories impacting Heron Therapeutics this week:

• Positive Sentiment: Heron agreed to sell substantially all of its assets to CorMedix in a deal reported at approximately $280 million, with $223 million upfront. The transaction could provide substantial proceeds, though it remains subject to completion. Asset purchase agreement details
• Neutral Sentiment: The sale would give CorMedix four products and broaden its reach in institutional care; the longer-term impact for Heron will depend on the transaction terms and its plans after transferring the assets. CorMedix acquisition overview
• Negative Sentiment: Third-quarter revenue fell 7.8% year over year to $35.3 million, below the $37.5 million analyst estimate. Heron’s loss of $0.03 per share matched consensus, however, and was narrower than the year-earlier loss of $0.05. Third-quarter 2026 results

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on HRTX shares. Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Thursday, October 15th. HC Wainwright cut shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen raised shares of Heron Therapeutics to a “sell” rating in a report on Saturday, August 8th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $2.00.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting. The company’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.